Notes in 11ProteinSynthesisInhibitors

To Subscribe, use this Key

Status	Last Update	Fields
Published	07/30/2024	The only antibiotic class of irreversible protein synthesis inhibitors are {{c1::aminoglycosides}}
Published	07/30/2024	Bacteria : {{c1::70S}} ribosomes :: Mammals : {{c1::80S}} ribosomes
Published	07/30/2024	Most protein synthesis inhibitors are administered {{c2::orally}}, EXCEPT for {{c1::Tigecycline & Streptogramins::2 answers}}
Published	07/30/2024	Broad Spectrum protein synthesis inhibitor subcategories:{{c1::Chloramphenicol, Tetracyclines}}
Published	07/30/2024	Moderate Spectrum protein synthesis inhibitor subcategories: {{c1::Macrolides, Ketolide}}
Published	07/30/2024	Narrow Spectrum protein synthesis inhibitor subcategories: {{c1::Lincosamides, Streptogramins, Linezolid}}
Published	07/30/2024	{{c1::Demeclocycline}} is not commonly used as an antibiotic. This is used for {{c2::syndrome of inappropriate ADH secretion (SIADH)}}.
Published	07/30/2024	Tetracyclines are available as {{c1::hydrochlorides}}. This makes them {{c2::more::less/more}} soluble, acidic, and stable.
Published	07/30/2024	Tetracyclines should not be taken with {{c1::divalent metal ions (milk), antacids, alkaline pH, food in general::food}}
Published	07/30/2024	Tetracyclines bind reversibly to the {{c1::30S}} subunit of the bacterial ribosome.
Published	07/30/2024	Tetracycline MoA: Blocks the binding of {{c2::aminoacyl-tRNA}} to the {{c1::acceptor}} site on the mRNA-ribosome complex.
Published	07/30/2024	Tetracycline Coverage: gram {{c1::(+) and gram (-)}}
Published	07/30/2024	For tetracycline-resistant strains, we can give {{c1::doxycyline}}, {{c1::minocycline}}, and {{c1::tigecycline}} as these drugs are poor subtrates of …
Published	07/30/2024	Tetracyclines that should be administered on an empty stomach are {{c1::Tetracycline and Demeclocycline}}
Published	07/30/2024	Tetracyclines that are not impaired by food are {{c1::Doxycycline and Minocycline}}
Published	07/30/2024	Tetracycline is absorbed in the {{c1::upper SI::organ}}
Published	07/30/2024	{{c1::F::T/F}}. Tetracyclines are widely distributed to tissues and body fluids including CSF.
Published	07/30/2024	Tetracyclines are contraindicated for {{c1::pregnant women}} and {{c2::children below 8 years old}}.
Published	07/30/2024	These induce hepatic metabolism and shorten the half-life of tetracyclines: {{c1::Carbamazepine, phenytoin, barbiturates (antiseizure drugs), and chro…
Published	07/30/2024	{{c1::Doxycycline}} and {{c1::tigecycline}} are the only two tetracyclines that are eliminated by {{c2::non-renal mechanisms (bile/feces)}}.
Published	07/30/2024	{{c1::Tigecycline}} is/are the longest acting tetracycline/s
Published	07/30/2024	{{c1::Doxycycline and Minocycline}} is/are long acting tetracycline/s
Published	07/30/2024	{{c1::Demeclocycline}} is/are intermediate acting tetracycline/s
Published	07/30/2024	{{c1::Tetracycline, Chlortetracycline, Oxytetracycline}} is/are short acting tetracycline/s
Published	07/30/2024	{{c1::Minocycline}} is the preferred tetracycline for treating patients who are meningococcal carriers
Published	07/30/2024	{{c1::Doxycycline}} is the preferred tetracycline for prophylaxis for protozoal infection (e.g., malaria), syphilis, and leptospirosis
Published	07/30/2024	Tetracyclines are the Drug of Choice for {{c1::Rocky Mountain spotted fever, Lyme disease, and Erlichia sp. infections::specific diseases}}
Published	07/30/2024	Tetracycline is included in regimens for {{c1::gastric and duodenal ulcer disease caused by Helicobacter pylori}}
Published	07/30/2024	Tetracyclines ADR: {{c1::GI irritation (nausea, vomiting, diarrhea), teratogenic (bones diorder, and teeth discoloration)}}
Published	07/30/2024	[VR]1. Tetracyclines2. C. difficile colitisA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does no…
Published	07/30/2024	The tetracyclines {{c1::minocycline and doxycycline}} have ototoxic effects
Published	07/30/2024	[VR]1. Expired tetracyclines2. Fanconi syndromeA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 doe…
Published	07/30/2024	[QC] Nephrotoxicity1. Tetracycline w/ diuretics2. Tetracyclines w/o diureticsA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	{{c1::Erythromycin}} is the prototype macrolide drug
Published	07/30/2024	[VR]1. [H+]2. ErythromycinA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not affect 2{{c1::B…
Published	07/30/2024	[VR]1. pH2. ErythromycinA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not affect 2{{c1::A}}
Published	07/30/2024	[QC] Erythromycin binds to:1. 30S subunit2. 50S subunitA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Erythromycin + Methyl group1. Azithromycin2. ClarithromycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Erythromycin + Methylated nitrogen1. Azithromycin2. ClarithromycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] CYP450 inhibition1. Azithromycin2. ClarithromycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] CYP450 inhibition1. Erythromycin2. ClarithromycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::C}}
Published	07/30/2024	[QC] Staphylococcal activity1. Azithromycin2. ClarithromycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Streptococcal activity1. Azithromycin2. ErythromycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] H. influenzae activity1. Azithromycin2. ClarithromycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] # of doses for chlamydial cervicitis & urethritis1. Azithromycin2. DoxycyclineA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[VR]1. Azithromycin2. QT intervalA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not affect 2…
Published	07/30/2024	[QC] Absorbability1. Azithromycin2. FidaxomicinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Clostridium difficile1. Azithromycin2. FidaxomicinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	{{c2::Ketolides}} are derived from {{c3::macrolides}} via the substitution of {{c1::3-keto group}} for the neutral sugar I-cladionse
Published	07/30/2024	[QC] Likeliness to prescribe Telithromycin1. Petients w/ Myasthenia gravis2. Patients w/o Myasthenia gravisA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[VR]1. Telithromycin2. CYP3A4 activityA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not aff…
Published	07/30/2024	Currently, {{c1::Telithromycin}} is the only member of {{c3::Ketolides}} as another drug named {{c2::Solithromycin}} is still pending approval.
Published	07/30/2024	{{c1::Clindamycin}} (a {{c2::Lincosamide::drug class}}) is a {{c3::chlorine}}-substituted derivative of {{c4::Lincomycin}}.
Published	07/30/2024	[VR]1. Resistance to macrolides2. Resistance to clindamycinA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Incre…
Published	07/30/2024	[QC] Clindamycin Excretion1. Bile2. UrineA. 1 > 2B. 1 < 2C. 1 = 2{{c1::C}}
Published	07/30/2024	[QC] Prophylaxis of endocarditis1. Clindamycin2. StreptograminA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Treatment of P. jiroveci pneumonia1. Clindamycin  + Primaquine2. Clindamycin + PyrimethamineA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Treatment of AIDS-related brain toxoplasmosis1. Clindamycin  + Primaquine2. Clindamycin + PyrimethamineA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B…
Published	07/30/2024	[QC] Treatment of periodontal abscesses1. Clindamycin  + Cephalosporin2. Clindamycin + PyrimethamineA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Treatment of penetrating abdominal wounds1. Clindamycin  + Cephalosporin2. Clindamycin + AminoglycosideA. 1 > 2B. 1 < 2C. 1 = 2{{c1::C…
Published	07/30/2024	[QC] Streptogramin A1. Quinupristin2. DalfopristinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Streptogramin B1. Quinupristin2. DalfopristinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[VR]1. Resistance to clindamycin2. Resistance to streptograminsA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. I…
Published	07/30/2024	Streptogramins are bactericidal except for {{c1::Enterococcus faecium}}
Published	07/30/2024	[QC] Streptogramins administration1. Oral2. IVA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Streptogramins Elimination1. Renal2. FecalA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[VR]1. Quinupristin-dalfopristin2. CYP3A4 activityA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 …
Published	07/30/2024	[VR]1. Quinupristin-dalfopristin2. Simvastatin duration of actionA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C.…
Published	07/30/2024	[VR]1. Quinupristin-dalfopristin2. Quetiapine metabolismA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase…
Published	07/30/2024	[QC] Streptogramin effectivity1. E. faecium2. E. faecalisA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	E. faecalis is resistant to streptogramins due to {{c1::an efflux-type of resistance mechanism::what type of resistance mechanism}}
Published	07/30/2024	[VR]1. Streptogramin2. Arthralgia-myalgia syndromeA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 …
Published	07/30/2024	[QC] Chlamydiae coverage1. Chloramphenicol2. DoxycyclineA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Chlorampenicol binds to1. 30S subunit2. 50S subunitA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[VR]1. Chlorampenicol acetyltransferase2. Chlorampenicol antibiotic activityA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decr…
Published	07/30/2024	[VR] 1. Hydrolysis2. Chloramphenicol succinateA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1…
Published	07/30/2024	[VR] 1. Hydrolysis2. ChloramphenicolA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not …
Published	07/30/2024	[QC] Chlorampenicol elimination1. Renal2. BiliaryA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[VR]1. Chlorampenicol in newborns2. Gray baby syndromeA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase i…
Published	07/30/2024	[VR]1. Penicillin allergy2. Prescription of chloramphenicolA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Incre…
Published	07/30/2024	[VR]1. Chloramphenicol2. RBC productionA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not af…
Published	07/30/2024	[VR]1. Premature infants2. Chloramphenicol doseA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 doe…
Published	07/30/2024	First class of {{c2::oxazolidinones}}: {{c1::Linezolid}}
Published	07/30/2024	[VR]1. Resistance to Macrolides2. Resistance to LinezolidA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increas…
Published	07/30/2024	[VR]1. 23S rRNA binding site mutation2. Resistance to LinezolidA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. I…
Published	07/30/2024	[VR]1. Linezolid2. CYP450 activityA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not affect …
Published	07/30/2024	[QC] Chlorampenicol administration1. Oral2. TopicalA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Linezolid administration1. Oral2. IVA. 1 > 2B. 1 < 2C. 1 = 2{{c1::C}}
Published	07/30/2024	[QC] Linezolid against streptococci 1. Bacteriostatic2. BactericidalA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Linezolid activity1. Gram (+) cocci2. Gram (+) rodsA. 1 > 2B. 1 < 2C. 1 = 2{{c1::C}}
Published	07/30/2024	[QC] Linezolid activity1. Gram (-) rods2. Gram (+) rodsA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Linezolid for TB1. 1st-line agent2. 2nd-line agentA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[VR]1. Linezolid2. Platelet countA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not affect 2…
Published	07/30/2024	[VR]1. Linezolid2. Risk for bleedingA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not affec…
Published	07/30/2024	[QC] MRSA coverage1. Linezolid2. Tedizolid phosphateA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Half-life1. Linezolid2. Tedizolid phosphateA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Hematologic-associated adversity1. Linezolid2. Tedizolid phosphateA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Dose given per day1. Linezolid2. Tedizolid phosphateA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Aminoglycoside coverage1. Gram (+)2. Gram (-)A. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Aminoglycoside1. Bacteriostatic2. BactericidalA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Aminoglycoside1. Reversible2. IrreversibleA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Aminoglycoside binding1. 30S subunit2. 50s subunitA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Aminoglycoside activity1. Alkaline pH2. Acidic pHA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[VR]1. pH2. Aminoglycoside activityA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not affect…
Published	07/30/2024	[QC] Combination with aminoglycosides1. Penicillin2. CephalosporinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Synergistic activity aminoglycosides1. Penicillin2. VancomycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::C}}
Published	07/30/2024	3 principal mechanisms of aminoglycoside resistance:1. {{c1::Treansferase enzyme production}}2. {{c2::Impaired entry}}3. {{c3::30S receptor protein mu…
Published	07/30/2024	[QC] Aminoglycoside absorption1. Oral2. ParenteralA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] CNS penetration1. Azithromycin2. AminoglycosideA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[VR]1. Aminoglycoside dose2. Bactericidal activityA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 …
Published	07/30/2024	[VR]1. Aminoglycoside dose2. NephrotoxicityA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does no…
Published	07/30/2024	[QC] Aminoglycoside efficacy1. Single large dose2. Multiple smaller dosesA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	{{c1::Post-antibiotic effect}}: Antibacterial activity persists beyond the time during which measurable drug is present.
Published	07/30/2024	3 properties of aminoglycosides:1. {{c1::Concentration Dependent}}2. {{c2::Post-antibiotic effect}}3. {{c3::Capable of synergistic killing (if combine…
Published	07/30/2024	[QC] Aminoglycoside toxicity1. Single large dose2. Multiple smaller dosesA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Aminoglycoside elimination1. Renal2. BiliaryA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[VR]1. Renal impairment2. Aminoglycoside daily dosingA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in…
Published	07/30/2024	[QC] Aminoglycoside1. Ototoxic2. NephrotoxicA. 1 > 2B. 1 < 2C. 1 = 2{{c1::C}}
Published	07/30/2024	[QC] Aminoglycoside Nephrotoxicity1. Aminoglycoside only2. Aminoglycoside + FurosemideA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Aminoglycoside Nephrotoxicity1. Aminoglycoside only2. Aminoglycoside + VancomycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[VR] 1. Streptomycin2. Vestibular damageA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does …
Published	07/30/2024	[VR] 1. Gentamicin2. Vestibular damageA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does no…
Published	07/30/2024	[VR] 1. Neomycin2. Auditory damageA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not af…
Published	07/30/2024	[VR] 1. Kanamycin2. Auditory damageA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not a…
Published	07/30/2024	[VR] 1. Amikacin2. Auditory damageA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not af…
Published	07/30/2024	[VR] 1. Neomycin2. NephrotoxicityA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not aff…
Published	07/30/2024	[VR] 1. Tobramycin2. NephrotoxicityA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not a…
Published	07/30/2024	[VR] 1. Gentamicin2. NephrotoxicityA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. Increase in 1 does not a…
Published	07/30/2024	[QC] Gentamicin 1. Auditory damage2. NephrotoxicityA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Gentamicin 1. Vestibular damage2. NephrotoxicityA. 1 > 2B. 1 < 2C. 1 = 2{{c1::C}}
Published	07/30/2024	[QC] Neomycin 1. Vestibular damage2. NephrotoxicityA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Neomycin 1. Auditory damage2. NephrotoxicityA. 1 > 2B. 1 < 2C. 1 = 2{{c1::C}}
Published	07/30/2024	[QC] Amikacin 1. Auditory damage2. NephrotoxicityA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[VR] 1. Aminoglycosides (very high doses)2. Respiratory muscle contractionA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a d…
Published	07/30/2024	[VR] 1. Aminoglycosides (very high doses)2. Respiratory paralysisA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease i…
Published	07/30/2024	[VR] 1. Aminoglycosides (very high doses)2. Use of calcium gluconateA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decreas…
Published	07/30/2024	[QC] Aminoglycoside prototype drug1. Streptomycin2. GentamicinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Streptomycin for TB1. 1st-line agent2. 2nd-line agentA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Streptomycin administration1. IV2. IMA. 1 > 2B. 1 < 2C. 1 = 2{{c1::C}}
Published	07/30/2024	[VR] 1. Streptomycin (in pregnancy)2. Deafness of newbornA. Increase in 1 leads to an increase in 2B. Increase in 1 leads to a decrease in 2C. In…
Published	07/30/2024	[QC] Bacterial conjuctivitis 1. Streptomycin2. GentamicinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Non-urinary tract infections1. Gentamicin alone2. Gentamicin + second agentA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Sore eyes1. Tobramycin2. StreptomycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Toxicity1. Amikacin2. KanamycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	Streptomycin-resistant strains of {{c2::M. tuberculosis}} are usually susceptible to {{c1::amikacin}}.
Published	07/30/2024	If the bacteria is resistant to all types of aminoglycosides, then we can opt for {{c1::netilmicin}}
Published	07/30/2024	[QC] Effectivity against visceral leishmaniasis1. Kanamycin2. ParomomycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Effectivity against MDR tuberculosis1. Kanamycin2. ParomomycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Used for bowel preparation for elective surgery1. Neomycin2. KanamycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	[QC] Neomycin, Kanamycin, Paromomycin coverage1. Gram (+)2. Gram (-)A. 1 > 2B. 1 < 2C. 1 = 2{{c1::C}}
Published	07/30/2024	[QC] Used for intestinal entamoeba histolytica infection1. Neomycin2. ParomomycinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	Plazomicin is derived from {{c1::sisomicin}}
Published	07/30/2024	[QC] Ototoxicity1. Streptomycin2. PlazomicinA. 1 > 2B. 1 < 2C. 1 = 2{{c1::A}}
Published	07/30/2024	Spectinomycin is structurally related to {{c1::aminoglycosides}}.
Published	07/30/2024	Spectinomycin is not an aminoglycoside because it lacks {{c1::amino acid}} sugars and {{c2::glycosidic}} bonds.
Published	07/30/2024	[QC] Drug of Choice for N. gonorrhea1. Spectinomycin2. CeftriaxoneA. 1 > 2B. 1 < 2C. 1 = 2{{c1::B}}
Published	07/30/2024	[QC] Doxcycline coverage1. Staphylococci2. StreptococciA. 1 > 2B. 1 < 2C. 1 = 2{{c1::C}}
Published	07/30/2024	Tetracycline resistance is main due to: 1. {{c1::Impaired Influx / Increased Efflux}}2. {{c1::Ribosome Protection}}3. {{c1::Enzymatic Inactivatio…
Status	Last Update	Fields